Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. But the last month did very little to improve the 57% share price decline over the last year.
Although its price has surged higher, Shanghai Junshi Biosciences’ price-to-sales (or “P/S”) ratio of 6.9x might still make it look like a buy right now compared to the Biotechs industry in Hong Kong, where around half of the companies have P/S ratios above 11.9x and even P/S above 26x are quite common. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.
Check out our latest analysis for Shanghai Junshi Biosciences
How Has Shanghai Junshi Biosciences Performed Recently?
Recent times haven’t been great for Shanghai Junshi Biosciences as…
